Claims
- 1. A compound having the formula (I): wherein R1 is a C2-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-8 cycloalkyl, C3-8 cycloalkenyl or cycloalkynyl, wherein said alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl or cycloalkynyl is optionally substituted with hydroxy, C1-5 alkoxy, C3-5 cycloalkoxy, halogen, oxo, carbamido, hydroxycarbamido, oximido, C1-5 alkyloximido, C3-5 cycloalkyloximido, C1-5 acyloximido or C3-5 cycloacyloximido; Q is methylene or ethylene; R3 is aryl or heteroaryl wherein said aryl or heteroaryl has one to three substituents selected from the group consisting of C2-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, C3-6 cycloalkenyl, cycloalkynyl, C3-5 alkylene, C3-5 cycloalkylene, haloC1-6 alkyl, haloC1-6 cycloalkyl, C3-5 cycloalkoxy, C1-2 alkylenedioxy, C1-6 acyl, C3-C10 cycloacyl, C1-6 acyloxy, .C3-6 cycloacyloxy, nitro or cyano; R8 is C1-5 alkyl, C2-5 alkenyl, C2-5 alkynyl, or C3-5 cycloalkyl optionally substituted by hydroxy, C1-5 alkyloxy, C3-5 cycloalkyloxy, C1-5 acyloxy, benzyloxy, C3-5 cycloacyloxy or halogen.
- 2. A compound of claim 1 which is 1-ethyl-8-isopropyl-3-(3,4-methylenedioxybenzyl)-xanthine.
- 3. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier or excipient.
- 4. A method of effecting PDE-IV inhibition for treating human patients suffering from a disease state selected from the group consisting of asthma, allergies, atopic diseases and rhinitis, comprising administering an effective amount of a compound having the formula (I): wherein R1 is a C2-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-8 cycloalky, C3-8 cycloalkenyl or cycloalkynyl, wherein said alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl or cycloalkynyl is optionally substituted with hydroxy, C1-5 alkoxy, C3-5 cycloalkoxy, halogen, oxo, hydroxycarbamido, oximido, C1-5 alkyloximido, C3-5 cycloalkyloximido, C1-5 acyloximido or C3-5 cycloacyloximido; Q is methylene or ethylene; R3 is aryl or heteroaryl wherein said aryl or heteroaryl has one to three substituents selected from the group consisting of C2-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, C3-6 cycloalkenyl, cycloalkynyl, C3-5 alkylene, C3-5 cycloalkylene, haloC1-6 alkyl, haloC1-6 cycloalkyl, hydroxy, C1-5 alkoxy, C1-2 alkylenedioxy, C1-6 acyl, C3-C10 cycloacyl, C1-6 acyloxy, C3-6 cycloacyloxy, halogen, nitro or cyano; R8 is C1-5 alkyl, C2-5 alkenyl, C2-5 alkynyl, or C3-5 cycloalkyl optionally substituted by hydroxy, C1-5 alkyloxy, C3-5 cycloalkyloxy, C1-5 acyloxy, benzyloxy, C3-5 cycloacyloxy or halogen.
- 5. The method of claim 4 wherein said compound is 3-(3,4-dimethoxybenzyl)-1-ethyl-8-isopropyl-xanthine.
- 6. A pharmaceutical composition as defined in claim 3, wherein the pharmaceutical acceptable carrier or excipient is selected from the group consisting of diluents, suspending agents, solubilizers, binders, disintegrants, preservatives, coloring agents, lubricants and combinations thereof.
- 7. A method of effecting PDE-IV inhibition in a human patient suffering from asthma, allergies, atopic diseases and rhinitis, comprising administering an effective amount of a compound of claim 1.
- 8. A compound having the formula (I): wherein R1 is a C3-8 cycloalkenyl or cycloalkynyl, wherein said cycloalkenyl or cycloalkynyl is optionally substituted with hydroxy, C1-5 alkoxy, C3-5 cycloalkoxy, halogen, oxo, carbamido, hydroxycarbamido, oximido, C1-5 alkyloximido, C3-5 cycloalkyloximido, C1-5 acyloximido or C3-5 cycloacyloximido; Q is methylene or ethylene; R3 is aryl or heteroaryl wherein said aryl or heteroaryl has one to three substituents selected from the group consisting of C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, C3-6 cycloalkenyl, cycloalkynyl, C3-5 alkylene, C3-5 cycloalkylene, haloC1-6 alkyl, haloC1-6 cycloalkyl, hydroxy, C1-5 alkoxy, C3-5 cycloalkoxy, C1-2 alkylenedioxy, C1-6 acyl, C3-C10 cycloacyl, C1-6 acyloxy, C3-6 cycloacyloxy, halogen, nitro or cyano; R8 is C1-5 alkyl, C2-5 alkenyl, C2-5 alkynyl, or C3-5 cycloalkyl optionally substituted by hydroxy, C1-5 alkyloxy, C3-5 cycloalkyloxy, C1-5 acyloxy, benzyloxy, C3-5 cycloacyloxy or halogen.
- 9. A method of effecting PDE-IV inhibition in a human patient suffering from asthma, allergies, atopic diseases and rhinitis, comprising administering an effective amount of a compound of claim 8.
- 10. A pharmaceutical composition comprising a compound of claim 8 and a pharmaceutical acceptable carrier or excipient.
- 11. A compound having the formula (I): wherein R1 is a C2-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-8 cycloalky, C3-8 cycloalkenyl or cycloalkynyl, wherein said alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl or cycloalkynyl is optionally substituted with hydroxy, C1-5 alkoxy, C3-5 cycloalkoxy, halogen, oxo, carbamido, hydroxycarbamido, oximido, C1-5 alkyloximido, C3-5 cycloalkyloximido, C1-5 acyloximido or C3-5 cycloacyloximido; Q is methylene or ethylene; R3 is aryl or heteroaryl wherein said aryl or heteroaryl has one to three substituents selected from the group consisting of C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, C3-6 cycloalkenyl, cycloalkynyl, C3-5 alkylene, C3-5 cycloalkylene, haloC1-6 alkyl, haloC1-6 cycloalkyl, hydroxy, C1-5 alkoxy, C3-5 cycloalkoxy, C1-2 alkylenedioxy, C1-6 acyl, C3-C10 cycloacyl, C1-6 acyloxy, C3-6 cycloacyloxy, halogen, nitro or cyano; R8 is C2-5 alkenyl or C2-5 alkynyl, optionally substituted by hydroxy, C1-5 alkyloxy, C3-5 cycloalkyloxy, C1-5 acyloxy, benzyloxy, C3-5 cycloacyloxy or halogen.
- 12. A method of effecting PDE-IV inhibition for treating human patients suffering from a disease state selected from the group consisting of asthma, allergies, atopic diseases and rhinitis, comprising administering an effective amount of a compound of claim 11.
- 13. A pharmaceutical composition comprising a compound of claim 11 and a pharmaceutical acceptable carrier or excipient.
Parent Case Info
This application claims the benefit of U.S. Provisional Application No. 60/070,649, filed Jan. 7, 1998.
US Referenced Citations (8)
Foreign Referenced Citations (10)
Number |
Date |
Country |
4707193 |
Mar 1994 |
AU |
2091249 |
Jul 1982 |
GB |
1156978 |
Jun 1989 |
JP |
5105631 |
Apr 1993 |
JP |
9618400 |
Jul 1982 |
WO |
WO8805306 |
Jul 1988 |
WO |
WO9424133 |
Oct 1994 |
WO |
WO9520589 |
Aug 1995 |
WO |
WO9748697 |
Dec 1997 |
WO |
WO9749702 |
Dec 1997 |
WO |
Non-Patent Literature Citations (2)
Entry |
Segura, J. Pharm. Pharmacol. 41, 129-131, 1989.* |
Merlos, Eur. J Med Chem 25, 653, 1989. |
Provisional Applications (1)
|
Number |
Date |
Country |
|
60/070649 |
Jan 1998 |
US |